PFE — Pfizer Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapSuper Stock

Annual cashflow statement for Pfizer, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	9,652	22,025	31,407	2,158	8,062
Depreciation
Deferred Taxes
Non-Cash Items	1,717	-3,147	1,016	5,868	2,836
Discontinued Operations
Extraordinary Items
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-275	12,804	-4,456	-2,174	-3,065
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	14,403	32,580	29,267	8,700	12,744
Capital Expenditures	-2,791	-2,711	-3,236	-3,907	-2,909
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-1,480	-19,835	-12,547	-28,371	5,561
Acquisition of Business
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-4,271	-22,546	-15,783	-32,278	2,652
Financing Cash Flow Items	11,121	16	-335	-632	-469
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-9,649	-9,816	-14,834	26,066	-17,140
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	475	159	-1,515	2,448	-1,810